Advertisement

Topics

Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.

08:00 EDT 30th March 2019 | BioPortfolio

Summary of "Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients."

Mutations in BRCA1 and BRCA2 genes predispose to breast and ovarian cancer with a high lifetime risk, whereas mutations in PALB2, CHEK2, ATM, FANCM, RAD51C, and RAD51D genes cause a moderately elevated risk. In the Finnish population, recurrent mutations have been identified in all of these genes, the latest being CHEK2 c.319+2T>A and c.444+1G>A. By genotyping 3156 cases and 2089 controls, we estimated the frequencies of CHEK2 c.319+2T>A and c.444+1G>A in Finnish breast cancer patients. CHEK2 c.319+2T>A was detected in 0.7% of the patients, and it was associated with a high risk of breast cancer in the unselected patient group (OR=5.40 [95% CI 1.58-18.45], p=0.007) and similarly in the familial patient group. CHEK2 c.444+1G>A was identified in 0.1% of all patients. Additionally, we evaluated the combined prevalence of recurrent moderate-risk gene mutations in 2487 breast cancer patients, 556 ovarian cancer patients, and 261 BRCA1/2 carriers from 109 families. The overall frequency of the mutations was 13.3% in 1141 BRCA1/2-negative familial breast cancer patients, 7.5% in 1727 unselected breast cancer patients, and 7.2% in 556 unselected ovarian cancer patients. At least one moderate-risk gene mutation was found in 12.5% of BRCA1 families and 7.1% of BRCA1 index patients, as well as in 17.0% of BRCA2 families and 11.3% of BRCA2 index patients, and the mutations were associated with an additional risk in the BRCA1/2 index patients (OR=2.63 [1.15-5.48], p=0.011]. These results support gene panel testing of even multiple members of breast cancer families where several mutations may segregate in different individuals. This article is protected by copyright. All rights reserved.

Affiliation

Journal Details

This article was published in the following journal.

Name: International journal of cancer
ISSN: 1097-0215
Pages:

Links

DeepDyve research library

PubMed Articles [31861 Associated PubMed Articles listed on BioPortfolio]

Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.

Invasive lobular carcinoma (ILC) of the breast has epidemiological, molecular and clinical specificities, and should likely be considered a unique entity. As for genetic susceptibility, CDH1 germline ...

Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk.

There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast c...

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

There is an unmet medical need for the treatment of recurrent ovarian cancer, and new approaches are needed to improve progression-free survival (PFS) and overall survival.

Prevalence, spectrum and founder effect of BRCA1 and BRCA2 mutations in Epithelial Ovarian Cancer from Middle East.

Germline mutations in Breast Cancer susceptibility gene 1 and 2 have previously been estimated to contribute to 13-18% of all Epithelial Ovarian Cancer (EOC). To characterize the prevalence and effect...

Hereditary breast cancer; Genetic penetrance and current status with BRCA.

The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1...

Clinical Trials [24445 Associated Clinical Trials listed on BioPortfolio]

Study of Individuals and Families at High Risk for Breast or Ovarian Cancer

RATIONALE: Studying individuals and families at high risk for breast or ovarian cancer may help in identifying the genes involved in the development of breast and ovarian cancer and help t...

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Compared to non-Latina Whites, Latinas have a higher prevalence of BRCA1/2 gene mutations but lower use of genetic cancer risk assessments services (GCRA). This study will develop and asse...

Lynne Cohen Consortium Project: Multi-Center Database/Registry

Goals of this registry: 1.1 To collect and store very limited demographic information (age, birthdate, race and ethnicity), limited cancer risk and breast and ovarian disease history, as ...

Risk-Reducing Surgeries for Hereditary Ovarian Cancer

Based on studies of "Inherited Susceptible Genes Among Epithelial Ovarian Cancer" (NCT03015376, clinicaltrials.gov) and "Cohort Study of Universal Screening for Lynch Syndrome in Chinese P...

Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region

A prospective, multi-centre, epidemiological observational study designed to evaluate the prevalence of BRCA1 and BRCA2 (BReast CAncer gene) mutations in current and newly diagnosed ovaria...

Medical and Biotech [MESH] Definitions

Autosomal dominant HEREDITARY CANCER SYNDROME in which a mutation most often in either BRCA1 or BRCA2 is associated with a significantly increased risk for breast and ovarian cancers.

A hereditary disease characterized by multiple ectodermal, mesodermal, and endodermal nevoid and neoplastic anomalies. Facial trichilemmomas and papillomatous papules of the oral mucosa are the most characteristic lesions. Individuals with this syndrome have a high risk of BREAST CANCER; THYROID CANCER; and ENDOMETRIAL CANCER. This syndrome is associated with mutations in the gene for PTEN PHOSPHATASE.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 17 at locus 17q21. Mutations of this gene are associated with the formation of familial breast and ovarian cancer. It encodes a large, nuclear protein that is a component of DNA repair pathways.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Article